DC Field | Value | Language |
---|---|---|
dc.contributor.author | Y W Lee | - |
dc.contributor.author | Y E Hwang | - |
dc.contributor.author | J Y Lee | - |
dc.contributor.author | Jung Hoon Sohn | - |
dc.contributor.author | Bong Hyun Sung | - |
dc.contributor.author | S C Kim | - |
dc.date.accessioned | 2018-07-19T16:30:06Z | - |
dc.date.available | 2018-07-19T16:30:06Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 1017-7825 | - |
dc.identifier.uri | 10.4014/jmb.1711.11025 | ko |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/17822 | - |
dc.description.abstract | RNA interference provides an effective tool for developing antitumor therapies. Cellpenetrating peptides (CPPs) are delivery vectors widely used to efficiently transport smallinterfering RNA (siRNA) to intracellular targets. In this study, we investigated the efficacy of the cancer-specific CPP carrier BR2 to specifically transport siRNA to cancer-target cells. Our results showed that BR2 formed a complex with anti-vascular endothelial growth factor siRNA (siVEGF) that exhibited the appropriate size and surface charge for in vivo treatment. Additionally, the BR2-VEGF siRNA complex exhibited significant serum stability and high levels of gene-silencing effects in vitro. Moreover, the transfection efficiency of the complex into a cancer cell line was higher than that observed in non-cancer cell lines, resulting in downregulated intracellular VEGF levels in HeLa cells and comprehensively improved antitumor efficacy in the absence of significant toxicity. These results indicated that BR2 has significant potential for the safe, efficient, and specific delivery of siRNA for diverse applications | - |
dc.publisher | Korea Soc-Assoc-Inst | - |
dc.title | VEGF siRNA delivery by a cancer-specific cell-penetrating peptide = 암세포 특이적 투과 펩타이드를 활용한 VEGF siRNA의 전달 | - |
dc.title.alternative | VEGF siRNA delivery by a cancer-specific cell-penetrating peptide | - |
dc.type | Article | - |
dc.citation.title | Journal of Microbiology and Biotechnology | - |
dc.citation.number | 3 | - |
dc.citation.endPage | 374 | - |
dc.citation.startPage | 367 | - |
dc.citation.volume | 28 | - |
dc.contributor.affiliatedAuthor | Jung Hoon Sohn | - |
dc.contributor.affiliatedAuthor | Bong Hyun Sung | - |
dc.contributor.alternativeName | 이영웅 | - |
dc.contributor.alternativeName | 황영은 | - |
dc.contributor.alternativeName | 이주영 | - |
dc.contributor.alternativeName | 손정훈 | - |
dc.contributor.alternativeName | 성봉현 | - |
dc.contributor.alternativeName | 김선창 | - |
dc.identifier.bibliographicCitation | Journal of Microbiology and Biotechnology, vol. 28, no. 3, pp. 367-374 | - |
dc.identifier.doi | 10.4014/jmb.1711.11025 | - |
dc.subject.keyword | Cancer-specific peptide | - |
dc.subject.keyword | Cell-penetrating peptide | - |
dc.subject.keyword | RNA interference | - |
dc.subject.keyword | Small-interfering RNA | - |
dc.subject.local | Cancer-specific peptide | - |
dc.subject.local | Cell-penetrating peptide | - |
dc.subject.local | RNA interference | - |
dc.subject.local | RNA Interference | - |
dc.subject.local | Small-interfering RNA | - |
dc.description.journalClass | Y | - |
There are no files associated with this item.
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.